A Study to Assess the Safety, Tolerability, Pharmacokinetics and Bioavailability of ORG-129 After Single and Multiple Ascending Oral Doses (Including Food Interaction Effect) in Healthy Young Volunteers
Latest Information Update: 07 Feb 2023
At a glance
- Drugs AGMB 129 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man
- Sponsors AgomAb Therapeutics; Origo Biopharma
- 02 Feb 2023 Results published in the AgomAb Therapeutics Media Release
- 13 Jan 2023 Status changed from active, no longer recruiting to completed.
- 01 Dec 2022 Planned number of patients changed from 56 to 80.